Introduction {#sec1-1}
============

Plantar fasciitis is a common musculoskeletal problem. It denotes a clinical condition of pain in the plantar aspect of the heel, characteristically worse on arising in the morning and after periods of prolonged sitting. The tender points are located at the plantar fascia origin on the medial process of the calcaneal tuberosity, and pain increases with passive stretching of the plantar fascia. The etiology of plantar fasciitis still remains unknown, and probably multifactorial, which include chronic inflammation, degeneration, and microtrauma of the plantar fascia, entrapment of lateral planter nerve, overuse syndrome, heel spurs, heel pad atrophy, and seronegative arthritis-induced inflammation\[[@ref1]-[@ref9]\]. Treatment modalities include physiotherapy, surgical release, nonsteroidal anti-inflammatory drugs (NSAIDs), extracorporeal shockwave therapy (ESWT), and corticosteroid injection (CSI)\[[@ref10]-[@ref13]\].

Recently, many studies have shown the efficacy of extracorporeal shock wave therapy (ESWT) for soft tissue. The outome may be highly dependent on machine type (electrohydraulic, electromagnetic, and piezoelectric systems) and treatment protocols\[[@ref4],[@ref5],[@ref13]\]. The energy levels are categorized into high (\>0.60 mJ/mm^2^), medium (0.28-0.59 mJ/mm^2^), and low (0.08-0.27 mJ/mm^2^)\[[@ref14]\]. Animal studies hint that there is a critical dose for tissue injury of ESWT on the rat Achilles tendon, and suggest 1000 impulses of 0.28 mJ/mm^2^ is a reasonable safe dose\[[@ref15]-[@ref16]\]. Side effects, such as bone marrow edema, osteonecrosis, and tendon ruptures are rare but occur in high energy shock wave therapy\[[@ref17]-[@ref20]\]. Many studies reveal that low energy ESWT for plantar fasciitis don't show evidence of clinical benefit over other non-operative modalities\[[@ref2],[@ref21],[@ref22]\].

Marier et al. reported that the presence of calcaneal bone marrow edema on pre-therapeutic MRI was a highly predictive variable for satisfactory clinical outcome of chronic plantar fasciitis treated by ESWT\[[@ref23]\]. Hammer and his colleagues reported that the thickness of the plantar fascia with plantar fasciitis under sonography decreased at the sixth month, and pain and walking time improved after moderate energy ESWT\[[@ref11]\].

In 2005, Porter et al. compared the efficacy of extracorporeal shock wave therapy (ESWT) and intralesional corticosteroid injection (CSI) for the treatment of plantar fasciopathy. They revealed corticosteroid injection was more efficacious and cost-effective than ESWT in the treatment of plantar fasciopathy. However, in 2012, Saber et al. performed a randomized controlled trial, that showed ESWT was as useful as CSI for relieving symptoms of plantar fasciitis. Therefore, the outcome of corticosteroid injection (CSI) and extracorporeal shock wave therapy (ESWT) as primary treatment of plantar fasciitis remains elusive\[[@ref25],[@ref26]\].

The purpose of the present study is not only to evaluate and compare the therapeutic effects of CSI and moderate energy ESWT in patients with chronic (\>2 months duration) symptomatic plantar fasciitis, but also further examine the correlation between the thickness changes and the clinical outcomes.

Materials and methods {#sec1-2}
=====================

Inclusion criteria {#sec2-1}
------------------

We enrolled 130 patients with chronic plantar fasciitis more than two months without injection history in the study between 2013 and 2014. 20 patients were excluded due to incomplete clinical follow-up or inadequate randomization. The 110 cases were randomly assigned to receive ESWT and CSI. 55 patients received ESWT and 55 patients received CSI. Generating a random allocation sequence include using a computer software program that generates the random sequence. <https://www.random.org/sequences/?min=1&max=100&col=2&format=html&rnd=new>. At final follow-up, 8 patients in ESWT group and 5 patients in CSI group didn't finish complete ultrasonography, VAS, or 100-points score records. There were 47 patients in ESWT group and 50 patients in CSI group completed the 3-months study.

These patients had been treated with plantar stretching exercise, gastrocnemius stretching, or shoe modification for one month, but showed little or no improvement before proceeding to ESTW or CSI treatment. Informed consents were obtained from all patients in accordance with the Declaration of Helsinki. This study had been approved by the ethics committee of the Institutional Review Board (IRB) in Show Chwan hospital (IRB No.1031203). Patients with a cardiac pacemaker, previous surgery involving the foot, autoimmune or systemic inflammatory disorder, coagulation disorder or anticoagulant, calcaneal fracture, infections, pregnancy and peripheral neuropathy, or accepting other therapeutic modalities were excluded. The bilateral plantar fasciitis was excluded to produce a more homogenous group. The average symptoms duration before visiting was about 2 months. After 1-month conservative treatment failure, the patients maybe enroll in this study.

Extracorporeal shock wave therapy (ESWT) {#sec2-2}
----------------------------------------

The ESWT technique followed the OrthospecTM device instrument guideline (Medispec, Montgomery Village, America). The shockwave probe of this device is wide focused type and energy level ranged from 0.07 to 0.32 mJ/mm^2^. All of these procedures were performed by Dr. Liu (12 years experienced orthopedic doctor). The patients started on the lowest intensity level 1 (0.07 mJ/mm^2^), and increased intensity level as patients' tolerance gradually to level 6 (0.29 mJ/mm^2^). The stable energy level 6 (0.29 mJ/mm^2^) was kept for 25 minutes to achieve total 1500 shock in each treatment. The operation time of each session of ESWT was about 30 minutes. The patients came to receive 2^nd^ section of ESWT 2 weeks after first ESWT. Two sessions of ESWT at an interval of 2 weeks was to avoid treatment induced heel pain or plantar fascia rupture due to median energy shock wave. The subjects will have temporary local tenderness subsided in three to four days after shockwave therapy.

Plantar fascia thickness evaluation {#sec2-3}
-----------------------------------

The high-resolution ultrasound (frequency transducers: 12 MHz, GE Healthcare Life Sciences, UK) used by radiologists to check the plantar fascia thickness. The plantar fascia thickness was measured at the plantar fascia insertion 5mm distal to calcaneus tuberosity. Each examination was repeated by the two radiologists independently and an average was taken. The radiologists were blinded of treatment methods (ESWT or CSI). The thickness of the plantar fascia was evaluated before ESWT or CSI, 4 weeks, and 12 weeks after first ESWT or steroid injection by radiologist using ultrasonography. Therefore, every patient received 6 times measurements from ultrasonography.

Corticosteroid injection (CSI) {#sec2-4}
------------------------------

CSI group after measure plantar fascia thickness, a small dot marker was made by radiologist under ultrasonography. For CSI, 20 mg triamcinolone acetonite with 2 ml 2% xylocaine were injected into the marker by Dr. Lai (10-years experience orthopedic doctor). The subjects will have temporary local pain at injection site about 2-3 days.

Outcome evaluation {#sec2-5}
------------------

Pain level and outcomes were recorded using visual analogue scale (VAS) (0-10) and 100-points scoring system (70 points for pain scores, 30 points for functional scores) at the start before ESWT or CSI, 4 weeks after first treatment, and 12 weeks after first treatment by Dr. Ma and Dr. Tan (20-years experience orthopedic doctor). In 100-points scoring system, the pain scores include pain on level walking, start up pain, and pressure pain. The functional scores include pain at work, pain during free times, and pain at night. Better function has a higher score. The details of 100-points scoring systems were demonstrated in a previous literature\[[@ref9]\]. The clinical outcomes using the visual analog scale (VAS) and 100-points scoring systems are recorded and compared at the 4^th^ week and 12^th^ week follow-up visit between CSI and ESWT. The present clinical trial study is designed to examine and compare the effect of the 2 treatment options, CSI and ESWT, on chronic plantar fasciitis.

Statistic analysis {#sec2-6}
------------------

Nonparametric tests were used in this study according to hypothesis tests for thickness of the plantar fascia, 10-point VAS, and 100-points scoring systems. The Mann-Whitney u test was performed for comparison of the thickness of the plantar fascia and pain scores between ESWT and CSI group. Spearman correlation coefficients were calculated between 4^th^ week thickness change of plantar fascia and 12th week clinical outcomes (VAS score and 100-point scoring) using SPSS software (Version 18.0 SPSS Inc., Chicago, IL).

Results {#sec1-3}
=======

There was no statistically significant difference between ESWT and CSI group in age, gender, location and duration of symptoms. As shown in \[[Table 1](#T1){ref-type="table"}\], in ESWT patients, the mean age is 54.53±8.62, and the gender ratio is 26:21 (female: male). The left leg plantar fascia number is roughly equal to the right leg number (23:24), and the average of duration of symptoms is 7.94±2.92 weeks. In CSI patients, the mean age is 54.58±8.63, and the gender of ratio is 28:22 (female: male). The left leg plantar fascia number is roughly equal to the right leg number (24:26), and the average duration of symptoms is 8.06±2.87 weeks. During the 12-week study period, no other treatment modalities are used in the study patients except short-term acetaminophen for pain relief after ESWT or steroid injection.

###### 

The basic characteristics of patients.

                                 ESWT         Corticosteroid injections   *p*-value
  ------------------------------ ------------ --------------------------- ----------------------------------------
  Clinical parameters            (N=47)       (N=50)                      
  Age (mean±SD)                  54.53±8.62   54.58 ±8.63                 0.834^[a](#t1f1){ref-type="table-fn"}^
  Range                                                                   
  Gender                                                                  
  Female                         26 (55.3)    28 (56.0)                   0.946^[b](#t1f2){ref-type="table-fn"}^
  Male                           21 (44.7)    22 (44.0)                   
  Leg                                                                     
  Left                           23 (48.9)    24 (48.0)                   0.927^[b](#t1f2){ref-type="table-fn"}^
  Right                          24 (51.1)    26 (52.0)                   
  Duration of symptoms (weeks)   7.94±2.92    8.06 ±2.87                  0.834^[a](#t1f1){ref-type="table-fn"}^

*ESWT: extracorporeal shock wave therapy*.

*Independent t-test for p-value*.

*Pearson Chi-square (x2) test for p-value*.

At fourth week, the mean thickness of the plantar fascia in ESWT group was from 0.37±0.07, to 0.46±0.08 cm. The mean thickness of the plantar fascia in CSI group was from 0.38±0.06, to 0.43±0.09 cm. There was a marginally statistical significance of thickness increase of the plantar fascia under ESWT in comparison to CSI treatment at 4^th^ week (P=0.048, [Table 2](#T2){ref-type="table"}). At the 12th week, the mean thickness of the plantar fascia of the ESWT group was from 0.37±0.07 to 0.38±0.07 cm, and the CSI group was from 0.38±0.06 to 0.39±0.07 cm ([Table 3](#T3){ref-type="table"}).

###### 

PF thickness, VAS, and 100-point scoring from pre-treatment to 4 weeks after treatment in patients who received ESWT and corticosteroid injections, respectively.

                      4 weeks after treatment   4 weeks after treatment                                             
  ------------------- ------------------------- ------------------------- ------------- --------------------------- -----------------------------------------
                      Baseline                  ESWT                      Baseline      Corticosteroid injections   p-value
  PF thickness        0.37 ±0.07                0.46 ±0.08                0.38 ±0.06    0.43 ±0.09                  0.048[\*](#t1f2){ref-type="table-fn"}
  VAS                 6.23 ±1.11                3.40 ±1.08                6.24 ± 1.10   4.10 ±0.81                  0.001[\*\*](#t1f1){ref-type="table-fn"}
  100-point scoring   31.74 ±4.61               72.11 ±11.09              31.84 ±4.44   70.38 ±8.55                 0.391
  Pain Scores         21.51 ±4.17               52.94 ±9.25               21.60 ±4.27   51.66 ±7.90                 0.466
  Functional Scores   10.23 ±2.26               19.17 ±3.45               10.24 ±1.52   18.72 ±1.49                 0.401

*PF: plantar fascia. VAS: 10-point visual analogue scale. ESWT: extracorporeal shock wave therapy. Mann-Whitney u test for comparison of the thickness of the plantar fascia and pain scores ESWT and CSI group for p-value*.

*: p\<0.01*,

*: p\<0.05*.

###### 

PF thickness, VAS, and 100-point scoring from pre-treatment to 12 weeks after treatment in patients who received ESWT and corticosteroid injections, respectively.

                      12 weeks after treatment   12 weeks after treatment                                             
  ------------------- -------------------------- -------------------------- ------------- --------------------------- ---------------------------------------------
                      Baseline                   ESWT                       Baseline      Corticosteroid injections   p-value
  PF thickness        0.37 ±0.07                 0.38 ±0.07                 0.38 ±0.06    0.39 ±0.07                  0.326
  VAS                 6.23 ± 1.11                1.34 ±1.24                 6.24 ±1.10    2.98 ± 0.84                 \<0.001[\*\*\*](#t3f1){ref-type="table-fn"}
  100-point scoring   31.74 ±4.61                85.28 ±12.61               31.84 ±4.44   76.36 ±10.25                \<0.001[\*\*\*](#t3f1){ref-type="table-fn"}
  Pain Scores         21.51 ±4.17                62.57 ±9.71                21.60 ±4.27   54.52 ±9.13                 \<0.001[\*\*\*](#t3f1){ref-type="table-fn"}
  Functional Scores   10.23 ±2.26                22.70 ±3.92                10.24 ±1.52   21.84 ±2.10                 0.177

*PF: plantar fascia. VAS: 10-point visual analogue scale. ESWT: extracorporeal shock wave therapy. Mann-Whitney u test for comparison of the thickness of the plantar fascia and pain scores ESWT and CSI group for p-value*.

*: p\<0.001*.

Our data show thickness of the plantar fasciitis in the measurement of baseline was not significantly associated the VAS score and 100-points scoring systems by stratifying \<4 mm and \>4 mm thickness of the plantar fasciitis (P=0.827 and P=0.814, respectively; data not shown). The \>4 mm thickness of the plantar fasciitis could not be associated refractory cases. Presently, the previous studies have not reported that refractory cases are associated with thickness of the plantar fasciitis. Overall, the plantar fascia thickness increased in both groups at the 4^th^ week, and more in ESWT than CSI under ultrasonography ([Figure 1A](#F1){ref-type="fig"}). However, the thickness at 12^th^ week decreased gradually than it at the 4^th^ week ([Figure 1A](#F1){ref-type="fig"}). But the average thickness remained slightly higher than the baseline. A representative plantar fascia picture of ultrasonography under ESWT at 0-week, 4-week and 12-week was shown in \[[Figure 1B](#F1){ref-type="fig"}, [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}\].

![(A) The ultrasonographic trend of thickness changes of plantar fascia in the extracorporeal shockwave therapy (ESWT) and corticosteroid injection (CSI) groups. (B) (C) (D) Representative patient of ESWT-induced thickness of plantar fascia were examined by ultrasonography at 0, 4-week, and 12-week follow-up. The thickness of plantar fascia increased at first month after ESWT, than decreased at 3rd month after treatment. PF: plantar fascia.](JMNI-18-047-g001){#F1}

In clinical outcome, the VAS score of ESWT group was lower than that of CSI group at 4-week and 12-week follow-up (P=0.001, P\<0.001) ([Table 2](#T2){ref-type="table"},[3](#T3){ref-type="table"}, [Figure 2A](#F2){ref-type="fig"}). In the 100-point scoring system, the scores were higher in ESWT group than those in CSI therapy at 12-week follow-up (85.28 versus 76.36, P\<0.001).

![**(A)** The visual analog scale (VAS) score and **(B)** 100-points scoring systems change for plantar fascia in the extracorporeal shock wave therapy and corticosteroid injection groups at 0, 4-week, and 12-week follow-up (\*, P\<0.05; \*\*, P\<0.01; \*\*\*, P\<0.001).](JMNI-18-047-g002){#F2}

In correlation analysis, it was found that thickness increase of plantar fascia at 4^th^ week was positively correlated with the VAS score at 12^th^ week (R=0.302, P=0.039) ([Table 4](#T4){ref-type="table"}). In total, 97 patients completed the parallel-randomized trial of CSI and ESWT. Collectively, ESWT was more efficacious than CSI in the treatment of plantar fasciitis in the 12-weeks assessment of VAS and 100-point score. The plantar fascia thickness increased from the baseline to 4^th^ week after treatment, then decreased gradually to 12^th^ week, but not to the baseline.

###### 

Spearman correlation coefficients, and p value between increase of plantar fascia thickness and 12^th^ week clinical outcomes (VAS score and 100-point scoring).

                Increase of plantar fascia thickness at 4^th^ week versus VAS score   Increase of plantar fascia thickness at 4^th^ week versus 100-point scoring   Increase of plantar fascia thickness at 12th week versus VAS score   Increase of plantar fascia thickness at 12th week versus 100-point scoring
  ------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------
  ESWT group                                                                                                                                                                                                                             
  Correlation   0.302                                                                 0.121                                                                         0.065                                                                0.133
  P-value       0.039[\*](#t4f1){ref-type="table-fn"}                                 0.419                                                                         0.664                                                                0.372
  CSI group                                                                                                                                                                                                                              
  Correlation   0.022                                                                 0.231                                                                         0.009                                                                0.065
  P-value       0.882                                                                 0.106                                                                         0.950                                                                0.651

*VAS: 10-point visual analogue scale. ESWT: extracorporeal shock wave therapy. Spearman's rank correlation coefficient for correlation coefficients and p value*.

*p\<0.05*.

Discussion {#sec1-4}
==========

The results of this study indicate that moderate energy ESWT is more effective in the management of chronic plantar fasciitis than corticosteroid injection. The difference increases gradually by time ([Figure 2A](#F2){ref-type="fig"}). These findings support and extend previous studies examining the relationship between ESWT for plantar fasciitis and treatment outcome. Moreover, the ultrasonographic findings in our study reveal that the thickness of plantar fascia increase under ESWT in the first month (from 0.37±0.07 to 0.46±0.08 cm), then gradually decrease to the baseline at the 3^rd^ month after treatment ([Figure 1](#F1){ref-type="fig"}). The increase of the plantar fascia thickness is in positive correlation to the clinical outcome ([Table 4](#T4){ref-type="table"}).

Previous studies examining the relationship between ESWT and CSI for plantar fasciitis had diverse outcomes on different machines, energy levels, and treatment protocols\[[@ref26]-[@ref30]\]. In 2005, Hammer et al. reported the thickness decreased gradually at 6 months after ESWT, and the clinical symptoms improved. However, the short-term ultrasonographic change of plantar fascia is still not reported. In our study, the thickness of plantar fascia increased at the first 4 weeks, and then it almost restored to the baseline at the 12^th^ week ([Table 3](#T3){ref-type="table"}, [Table 4](#T4){ref-type="table"}, and [Figure 1A](#F1){ref-type="fig"}). We predict it will decrease contineously as Hammer's report at 6 months after ESWT. However, we have no long term follow to come to this conclusion\[[@ref12]\].

In 2002 and 03, Wang et al. reported molecular studies of ESWT. The rise of angiogenic markers occurred in as early as one week and only lasted for approximately 8 weeks, whereas the neovascularization was first noted in 4 weeks and persisted for 12 weeks or longer along with cell proliferation\[[@ref31]\]. Under the mechanism, the thickness of plantar fascia should increase in the early stage after ESWT. Our study results supported this phenomenon. Additionally, shock waves have been used in the treatment of calcified tendonitis of the rotator cuff, nonunion of bone, chronic tennis elbow, and painful heel syndrome\[[@ref11],[@ref13],[@ref17],[@ref19]\]. The efficacy of ESWT was controversial in previous studies. The success rates range from 40% to 80%\[[@ref16],[@ref21],[@ref24],[@ref32]\], and the results are affected by symptom duration\[[@ref33]\]. The machine type and the delivered energy level are different in different studies\[[@ref34]-[@ref35]\]. We used the moderate energy level, two-session strategy, large therapy zone ESWT machine to reduce inter-treatment bios. In clinical outcome, the results of the VAS score and 100-point scoring revealed that moderate energy ESWT was more effective than CSI in the management of chronic plantar fasciitis. No osteonecrosis or tendon rupture occurred in our study.

The ultrasonographic evaluation of plantar fasciitis is a powerful and cost-effective tool\[[@ref36]-[@ref37]\]. The cost of ultrasonography is much lower than MRI. In Taiwan, the ultrasonography was 1800 NTD (55 USD), and MRI was 8500 NTD (271 USD). Under MRI evaluation, moderate or marked hyperemia was found in the plantar fascia and surrounding tissue along the insertion in plantar fasciitis history shorter than 6 months\[[@ref38]\]. Our study revealed increased thickness of the plantar fascia at 4^th^ week after ESWT ([Table 2](#T2){ref-type="table"}).

Except plantar thickness by using ultrasonography, a similar concept in a previous study showed magnetic resonance imaging (MRI) was a desirable assessment for the increase of soft-tissue edema on acute response in that it could help a physician to control the effectiveness of the magnitude of ESWT energy\[[@ref41]\].

Additionally, we did not attempt to measure thickness of the plantar fascia of the normal foot in these patients to reproduce the same results as previous studies. It was one of the limits of this study. Nonetheless, some aspects of comparison between ESWT and CSI remained elusive. Therefore, our study focused on the thickness change of plantar fascia before and after treatment, and clinical outcomes between ESWT and CSI in the short-time 3-month follow-up.

The systematic review of the Physiotherapy Evidence Database showed that there is no consensus in the literature about the difference between low- and high-energy ESWT devices. Generally, the safety and efficacy of ESWT is clearly supported by the cumulative data\[[@ref39]\]. The ethnic differences of body mass index (BMI) distribution were presented within a lower and narrower BMI range for Chinese compared to Blacks and Whites, who have a higher mean BMI\[[@ref40]\]. Therefore, we use the medium energy ESWT (1500 pulses for two sections) for chronic plantar fasciitis to avoid osteonecrosis of foot. That was consistent within a previous review study\[[@ref39]\].

This study had other limitations. First, in the 130 cases study, twenty cases didn't fulfill study criteria due to selection and blindness. Furthermore, there were 8 cases in ESWT and 5 cases in CSI dropped out this study. The data may be different if all the patients finish this study. Large sample size study is required to confirm this result. Second, we performed median energy ESWT (0.29 mJ/mm^2^) 1500 shocks for 2 sections. Could different treatment protocols or shock wave energy produce the same results remains unclear. Third, we stop assessment at 3 months not 12 months due to the limited budgets and staffs to connect with 97 plantar fasciitis patients. Therefore, we can't compare our results with other long-term studies. We didn't restrict patients' activity level over 3 months due to impracticable situation in some high activity demand patients (farmers, constructors). During the 3-months study, all the patients were advised to prevent level I and II exercise or long distance walk (over 5 kilometers).

Another defect of this study is the long-term effects of ESWT and CSI. We didn't follow these patients long enough to evaluate the recurrence rate, the possible complications of osteonecrosis of calcaneus, or plantar fascia rupture. During this study period, some patients got post-ESWT and post-CSI heel pain. Most patients' symptoms relieved after oral acetaminophen. Further long-term follow studies are mandatory.

Conclusion {#sec1-5}
==========

Our study revealed that ESWT is more efficacious than CSI in the treatment of plantar fasciitis in the 12-weeks assessment of VAS and 100-point score. The plantar fascia thickness increased from the baseline to 4^th^ week after treatment, then decreased gradually, but not to the baseline. Under ESWT, the increase of plantar fascia thickness at 4^th^ week was positively correlated with the VAS score at 12^th^ week. It implied more change in plantar fascia at early stage after ESWT, more effective of the therapeutic effect. In CSI, no such correlation was noted.

ESWT

:   Extracorporeal Shockwave Therapy

CSI

:   Corticosteroid Injections
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